1. Home
  2. BW vs URGN Comparison

BW vs URGN Comparison

Compare BW & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Babcock & Wilcox Enterprises Inc.

BW

Babcock & Wilcox Enterprises Inc.

HOLD

Current Price

$14.32

Market Cap

919.9M

Sector

Industrials

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$17.98

Market Cap

922.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BW
URGN
Founded
1867
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Building Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
919.9M
922.1M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
BW
URGN
Price
$14.32
$17.98
Analyst Decision
Buy
Strong Buy
Analyst Count
3
7
Target Price
$7.00
$29.29
AVG Volume (30 Days)
5.7M
796.5K
Earning Date
03-04-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,128,000.00
Revenue This Year
$41.58
$127.17
Revenue Next Year
$66.70
$73.82
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$3.42
52 Week High
$16.24
$30.00

Technical Indicators

Market Signals
Indicator
BW
URGN
Relative Strength Index (RSI) 57.32 41.03
Support Level $8.03 $17.07
Resistance Level N/A $20.44
Average True Range (ATR) 1.61 0.87
MACD 0.06 -0.05
Stochastic Oscillator 68.98 39.40

Price Performance

Historical Comparison
BW
URGN

About BW Babcock & Wilcox Enterprises Inc.

Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: